Media headlines about AcelRx Pharmaceuticals (NASDAQ:ACRX) have been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 46.1802522301182 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of brokerages have commented on ACRX. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, October 27th. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Royal Bank of Canada reduced their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Friday, October 13th. Jefferies Group downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $6.18.
AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at $2.15 on Tuesday. AcelRx Pharmaceuticals has a fifty-two week low of $1.55 and a fifty-two week high of $5.75. The company has a current ratio of 4.78, a quick ratio of 4.71 and a debt-to-equity ratio of -0.43. The stock has a market cap of $108.23, a PE ratio of -1.92 and a beta of 2.96.
In related news, Director Mark G. Edwards acquired 30,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were purchased at an average price of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the director now directly owns 150,000 shares in the company, valued at approximately $285,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 28.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact AcelRx Pharmaceuticals (NASDAQ:ACRX) Share Price” was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-acelrx-pharmaceuticals-acrx-share-price/1819974.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.